Angiotensin-converting enzyme inhibitory effects of dairy- and soy-derived peptides in pre-hypertensive overweight men and wom by Melissa S. Munn et al.
Functional Foods in Health and Disease 2013, 3(1):37-47     Page 37 of 47 
Short Report                                                                                                               Open Access 
 
Angiotensin-converting enzyme inhibitory effects of dairy- and soy-derived 
peptides in pre-hypertensive overweight men and women 
 
Melissa S. Munn
1, Shalamar Sibley
2, Richard Brundage 
3, Baraem Ismail
1, Carrie P. 
Earthman
1 
 
1Department  of  Food  Science  and  Nutrition,  University  of  Minnesota,  1334  Eckles  Avenue, 
Saint Paul, MN 55108, USA; 
2Department of Medicine, University of Minnesota, 420 Delaware 
Street,  SE,  Minneapolis,  MN  55455,  USA; 
3Department  of  Experimental  and  Clinical 
Pharmacology, University of Minnesota, 717 Delaware Street SE, Minneapolis, MN 55414, USA 
 
*Corresponding Author: Carrie P Earthman, PhD, RD, University of Minnesota, Department 
of Food Science and Nutrition, 1334 Eckles Avenue, St. Paul, MN 55108, USA 
 
Submission  date:  December  18,  2012,  Acceptance  date:  January  24,  2013;  Publication  date: 
January 27, 2013 
 
 
ABSTRACT: 
 
Background:  Hypertension  is  considered  the  most  prevalent  cardiovascular  disorder  and  a 
significant public health problem.  A functional food that could potentially impede progression 
into a hypertensive state in pre-hypertensive individuals is of significant interest to clinicians and 
consumers.  In vitro and animal studies suggest the presence of potential ACE inhibitory dairy- 
and  soy-derived  peptides.    Very  few  human-based  research  studies  have  been  conducted  to 
investigate the blood pressure lowering and/or ACE-inhibitory effects of whey and soy protein 
hydrolysates in humans.  This pilot study tested the acute effects of 20g doses of whey and soy 
hydrolysates in pre-hypertensive, overweight men and postmenopausal women on serum ACE 
activity and blood pressure.  
 
Findings: Using a randomized crossover design, four initial subjects received five treatments 
(unhydrolyzed casein, whey protein isolate, whey protein hydrolysate, soy protein isolate, soy 
protein hydrolysate) at different testing visits separated by three-day washout periods. Blood 
pressure  and  blood  draws  to  measure  ACE  activity  were  taken  at  thirty  minute  intervals 
following  treatment  consumption.    Both  the  soy  protein  and  whey  protein  hydrolysates  had 
notable in vitro ACE-inhibitory activity, both before and after heat treatment.  No differences 
were observed among the protein treatments for either ACE activity or systolic blood pressure.   
 
Conclusions:  The results of this pilot study support a discrepancy between in vitro and human-
based in vivo ACE-inhibitory acute effects of whey and soy protein hydrolysates, underscoring 
the need for further research to better understand potential explanations for these findings.  Functional Foods in Health and Disease 2013, 3(1):37-47     Page 38 of 47 
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INTRODUCTION:  
The  renin-angiotensin-aldosterone  system  (RAAS)  primarily  increases  blood  pressure  by 
producing  the  vasoconstrictor  angiotensin  II,  facilitated  by  angiotensin-converting  enzyme 
(ACE).  Researchers have found antihypertensive potential in dairy-derived peptides [1-6].  The 
development of functional foods that may prevent hypertension in pre-hypertensive individuals 
is intriguing.  We investigated the effects of an acute dose of whey- and soy-derived bioactive 
peptides  on  ACE  activity  and  blood  pressure  in  pre-hypertensive,  overweight  men  and 
postmenopausal women. 
 
METHODS:  
Study  Overview:  This  randomized,  single-blind  cross-over  study  compared  whey  protein 
hydrolysate (WPH), whey  protein isolate (WPI), soy  protein hydrolysate (SPH), soy protein 
isolate (SPI), and casein at 20g doses, an amount expected to elicit a biological effect based on a 
study reporting significant blood pressure reduction in humans consuming 20g WPH for six 
weeks  [7].    To  determine  acute  effects,  measurements  were  taken  up  to  180  minutes  post-
treatment. See Figure 1 for study design.  
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 Figure 1.  Study Design: A Sample Schedule 
 
*Each subject received the five treatments in a randomized order, each at a different visit: soy protein 
isolate  (SPI),  soy  protein  hydrolysate  (SPH),  whey  protein  isolate  (WPI),  whey  protein  hydrolysate Functional Foods in Health and Disease 2013, 3(1):37-47     Page 39 of 47 
(WPH), casein.  A controlled diet was followed throughout the study, beginning one week before testing; 
treatments were separated by 3-day washout periods. X: No treatment received 
 
Subject  Selection:  Subjects  were  recruited  through  University  of  Minnesota  Institutional 
Review Board (IRB)-approved campus fliers.  The study protocol was reviewed and approved by 
the IRB and the Clinical and Translational Science Institute at the University of Minnesota. See 
Table 1 for recruitment eligibility.   
 
Table 1.  Study Eligibility 
 
Body mass index (BMI)    25 – 34.9 kg/m
2   
Age        ≥ 40 years       
SBP
*¥         ≥ 90 but ≤139 mm Hg 
and/or 
DBP
†≦        ≤ 90 but > 80  
 
Pertaining to females only: 
No Menses for ≥ 12 months  
No hormone replacement therapy medications
 
Had a complete hysterectomy ≥ 12 months prior to enrollment
 
 
 
* SBP: Systolic blood pressure 
†DBP:
 Diastolic blood pressure
 
¥ Taken as the mean of 2 readings 
 
 
Testing Visits: Subjects arrived to the DCRU by 0700 fasted from 1900 the day before and were 
instructed to lie supine with one pillow beginning 30 minutes before baseline, after which blood 
pressure assessment and blood draw for ACE activity were performed.  Subjects consumed one 
of the five randomly assigned treatments, after which the Time 0 was marked.  Blood sampling 
occurred  at  30-minute  intervals  from  Time  0  to  180  minutes,  determined  from  a  small 
preliminary  study    where  nine  subjects  received  20g  of  one  of  the  treatments  and  blood 
collection occurred at 15- and 30-minute intervals up to 300 minutes.   
 
Controlled Diet: DCRU Nutrition Services designed a controlled diet to meet individual energy 
needs that was whey-, soy-, and dairy-free, providing 1g of sodium and 1.5g of potassium per 
1,000 calories.   All meals were provided and subjects were to report off-plan intake on food 
records and to return remains. 
 
Production of hydrolysates:   
Davisco Foods International, Inc. (Eden Prairie, MN) provided the WPI (BiPro) and WPH  
(Biozate 1).  Archer Daniels Midland Company provided defatted soy flour samples (Decatur, 
IL).  Minimally heat-treated and defatted soy flour was used to prepare SPI following methods Functional Foods in Health and Disease 2013, 3(1):37-47     Page 40 of 47 
outlined by Tsumura et  al [8].  Produced SPI  was  used to  prepare  SPH following  selective 
hydrolysis with papain, mainly targeting hydrolysis of the β-conglycinin component [9].   
 
Production of treatment cookies: Whey-derived peptides are typically delivered in beverages 
[3,7].    The  insolubility  of  SPH  in  liquid  and  desire  for  optimal  palatability  influenced  our 
decision to utilize the unique delivery form of a cookie.  Twenty grams of the protein were 
divided into four cookies (Table 2) baked in a conventional oven at 449.7 K for seven minutes.   
 
     Table 2.  Protein Treatment Ingredients                                                                              
Ingredient   Amount (g)*  
Protein**   24.83  
Butter   21.59  
Starch   21.59  
Brown sugar   16.198  
Splenda   1.94  
Baking soda   0.539  
Baking powder   0.269  
Almond flavor   0.2159  
Vanilla flavor   2.159  
Walnut oil   2.159  
Water   18.358  
Chocolate chips   15.118  
Total⁺ per cookie⁺⁺  125⁺  28.94⁺⁺ 
 
 
* Amounts have been scaled up to account for losses during preparation                                                                                                 
** Casein, soy protein hydrolysate, soy protein hydrolysate, whey protein isolate, or whey     protein 
hydrolysate                  
⁺ Total weight of dough before dividing into 4 cookies                                                                                                          
⁺⁺ Weight of each of the 4 cookies  
  
In vitro ACE inhibition of hydrolysates before and after heating: ACE inhibitory activity 
measurements of the hydrolysates were conducted, in triplicate, following the assay outlined by 
Otte et al [10] and Shalaby et al [11] using FA-PGG as substrate, with modifications adapted 
from Margatan et al [9].  The influence of thermal or pH instability on bioactivity or digestive 
survivability of peptides after baking is uncertain; therefore, SPH ACE inhibition was tested post 
thermal treatment similar to cookie baking conditions.  In vitro inhibition was unaffected by heat 
treatment (data published elsewhere) [9]. Functional Foods in Health and Disease 2013, 3(1):37-47     Page 41 of 47 
Plasma ACE Activity Assay: At each time point, blood was collected (5mL), clotted, held at 
room temperature, and cold spun at 2091 RCF for 10 minutes.  Serum (1mL) was aliquotted into 
cryogenic vials in duplicate, flash frozen with dry ice and alcohol, and stored at 210.8 K before 
shipment on dry ice to ARUP Laboratories (Salt Lake City, UT).   
 
Statistical Analysis: Area under the curve (AUC) was calculated for each subject and treatment 
for ACE activity and systolic blood pressure (SBP) from baseline to 180 minutes ((Phoenix 
WinNonlin 6.3, Mountain View, CA, USA)).  Because in vivo digestion of WPI, SPI, and casein 
could yield ACE-inhibitory peptides, differences across all treatments for both endpoints were 
evaluated  using  repeated  measures  ANOVA  with  post-hoc  comparisons  ((GraphPad  InStat 
version  3.10  for  Windows  (GraphPad  Software,  San  Diego  California  USA, 
www.graphpad.com)).  Significance was set at p <0.05.   
 
 
RESULTS: 
In vitro ACE inhibition of the SPH and WPH samples were similar, (IC50 of 0.177mg SPH 
protein/mL, 0.200mg WPH protein/mL [9] and fell within the reported range of IC50 values for 
ACE  inhibitory  peptides  (0.046-0.930  mg  protein/mL)  [12-16].    No  adverse  events  were 
reported, treatments were tolerated, and compliance was good.  However, logistical challenges 
with study continuation encouraged an interim analysis of data from the first four subjects.  A 
lack  of  significant  differences  between  treatment  proteins  on  either  endpoint  halted  subject 
recruitment.  Data from these four subjects are presented.  See Table 3 for subject characteristics. 
Graphical  representation  of  mean  ACE  activity  (Figure  2)  and  SBP  (Figure  3)  over  time, 
illustrate the variability among treatments. 
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          Figure 2.  Mean ACE Activity vs Time by Treatment Functional Foods in Health and Disease 2013, 3(1):37-47     Page 42 of 47 
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Figure 3. Mean Systolic Blood Pressure vs Tme by Treatment 
 
 
 
 
                         Table 3.  Subject Characteristics 
 
N                  4 (2M, 2F) 
Age
*      58 ±1.3 years 
BMI
*      28±.7 kg/m
2 
SBP
*       118±7 mm Hg 
DBP
* †      81±6 mm Hg 
 
                            *Mean ± standard deviation 
† Prehypertension may be defined by a DBP >80 mmHg 
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   Table 4.  Angiotensin-Converting Enzyme (ACE) Area-Under-the-Curve (AUC) by Treatment 
 
Treatment  Subject ID 
AUC 60-180 
min  AUC 0-180 min 
 
 
Casein 
85001  3825  6150 
85004  5445  7980 
85005  7110  10785 
85007  4170  6270 
Mean  5138  7796 
SD  1488  2161 
 
 
SPI 
85001  3405  4845 
85004  4845  7290 
85005  6892.5  10485 
85007  4575  6900 
Mean  4958  7429 
SD  1620  2272 
 
 
SPH 
85001  3405  4845 
85004  4845  7290 
85005  6892.5  10485 
85007  4680  7035 
Mean  4956  7414 
SD  1443  2323 
 
 
WPI 
85001  3885.00  5475.00 
85004  5490.00  8310.00 
85005  6630.00  10335.00 
85007  4080.00  6180.00 
Mean  5021.250  7575 
SD  1289  2200 
 
 
 
WPH 
85001  4410.00  6675.00 
85004  4545.00  7155.00 
85005  6930.00  10965.00 
85007  4050.00  6495.00 
Mean  4984  7823 
SD  1314  2113 
 
Abbreviations:  Soy protein isolate (SPI), soy protein hydrolysate (SPH), whey protein isolate (WPI), 
whey protein hydrolysate (WPH), casein 
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    Table 5.  Systolic Blood Pressure Area-Under-the-Curve (AUC) by Treatment 
 
Treatment  Subject ID 
AUC 60-180 
min 
AUC 0-180 
min 
 
 
Casein 
85001  11280  16800 
85004  15360  22830 
85005  12045  18135 
85007  14580  21195 
Mean  13316  19740 
SD  1961  2762 
 
 
SPI 
 
85001  11190  16860 
85004  14790  22245 
85005  13125  20250 
85007  13320  20085 
Mean  13106  19860 
SD  1478  2228 
 
 
 
SPH 
 
 
 
 
85001  11625  17205 
85004  16140  24480 
85005  12810  19020 
85007  13275  19875 
Mean  13463  20145 
SD  1915  3097 
 
 
 
WPI 
 
85001  11055  16770 
85004  14715  22005 
85005  12885  19230 
85007  13320  19740 
Mean  12994  19436 
SD  1510  2148 
 
 
 
WPH 
 
85001  10890  16470 
85004  15495  23850 
85005  11730  17430 
85007  13260  19680 
Mean  12844  19358 
SD  2022  3283 
 
Abbreviations:  Soy protein isolate (SPI), soy protein hydrolysate (SPH), whey protein isolate (WPI), 
whey protein hydrolysate (WPH), casein Functional Foods in Health and Disease 2013, 3(1):37-47     Page 45 of 47 
DISCUSSION: 
Differences  between treatments were undetected and no treatment lowered  SBP or inhibited 
ACE to any observable degree.  Strengths include use of a cross-over design, inclusion of in vitro 
ACE activity measurements, and a diet controlling potassium and sodium for consistency with 
close monitoring of compliance.  However, only an acute dose of 20g was tested. This amount 
may be insufficient; studying the effects of multiple doses, or chronic dosing, over time would be 
more informative.  Additionally, subjects were either mildly pre-hypertensive or normotensive; 
ACE-inhibitory  potential  may  be  more  evident  in  pronounced  hypertension.  Other  RAAS 
proteins  were  unevaluated  to  support  or  negate  the  proposition  of  ACE  inhibition  as  the 
mechanism  for  reduced  blood  pressure.  Finally,  peptides  were  delivered  in  baked  cookies.  
While  heat  stability  in  ACE-inhibitory  activity  was  confirmed,  stability  to  increased  pH 
(potentially following added sodium bicarbonate and baking powder) is unknown.  Although 
uncertain, pH and heat synergism and reactions occurring in heat conditions between proteins 
and reducing sugars, like the Maillard reaction, may influence bioactivity; these were not directly 
evaluated.  Work is needed to determine optimal delivery to humans.  
In conclusion, an acute dose of 20g of either SPH or WPH when delivered in a uniquely 
formulated cookie did not reduce SBP or ACE activity. Discrepancies between in vitro ACE 
inhibition  by  SPH  and  WPH  and  inadequate  in  vivo  evidence  warrant  further  research, 
particularly to determine peptide bioavailability for optimal dosing to achieve biological effects.   
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